Drug search by name

Foscarnet and Dehydration

Result of checking the interaction of drug Foscarnet and disease Dehydration for safety when used together.

Check result:

Foscarnet <> Dehydration

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Foscarnet is nephrotoxic. Foscarnet crystals may deposit in renal tubules and capillaries, sometimes causing acute tubular necrosis and renal failure. Foscarnet may also concentrate in the urine and cause penile or vulvovaginal irritation. Adequate hydration is crucial to minimize the risk of renal damage and genital ulcerations. Generally, foscarnet should be administered by an infusion pump over 1 to 2 hours accompanied by hydration. The manufacturer recommends 750 to 1000 mL of normal saline or 5% dextrose solution prior to the first infusion of foscarnet to establish diuresis, then 500 mL (for 40 to 60 mg/kg dose of foscarnet) or 750 to 1000 mL (for 90 to 120 mg/kg dose of foscarnet) of hydration fluid concurrently with each subsequent foscarnet infusion. Patients who are dehydrated may be at increased risk for the development of nephrotoxicity and may benefit from additional hydration if tolerated.

References:

Deray G, Le Hoang P, Soubrie C, et al "Foscarnet-induced acute renal failure and effectiveness of haemodialysis." Lancet 2 (1987): 216
Evans LM, Grossman ME "Foscarnet-induced penile ulcer." J Am Acad Dermatol 27 (1992): 124-6
Sohl Akerlund A, Keisu M, Lernestedt JO, Sandberg M "Penile ulcerations in connection with foscarnet therapy. Clinical picture and incidence." Int Conf AIDS 9 (1993): 358
"Product Information. Foscavir (foscarnet)." Astra USA, Westborough, MA.
Chrisp P, Clissold SP "Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis." Drugs 41 (1991): 104-29
Cacoub P, Deray G, Baumelou A, et al "Acute renal failure induced by foscarnet: 4 cases." Clin Nephrol 29 (1988): 315-8
Caumes E, Gatineau M, Bricaire F, Dohin E, Katlama C, Gentilini M "Foscarnet-induced vulvar erosion." J Am Acad Dermatol 28 (1993): 799
Deray G, Martinez F, Katlama C, et al "Foscarnet nephrotoxicity: mechanism, incidence and prevention." Am J Nephrol 9 (1989): 316-21
Moyle G, Barton S, Gazzard BG "Penile ulceration with foscarnet therapy." AIDS 7 (1993): 140-1
Navarro JF, Quereda C, Moreno A, Quereda C "Renal tubular acidosis following treatment with foscarnet." AIDS 9 (1995): 1389-90
Gilquin J, Weiss L, Kazatchkine MD "Genital and oral erosions induced by foscarnet." Lancet 335 (1990): 287
Saint-Marc T, Fournier F, Touraine J-L, Marneff E "Uvula and oesophageal ulcerations with foscarnet." Lancet 340 (1992): 970-1
Jacobson MA "Review of the toxicities of foscarnet." J Acquir Immune Defic Syndr 5 (1992): s11-7
Holbrook J, Jabs D, Jacobson M, Mendez P, Min Y, Murphy R "Foscarnet-related abnormalities in serum creatinine, calcium, and magnesium in patients with CMV retinitis. The SOCA Research Group." Int Conf AIDS 9 (1993): 361
Fegeuex S, Salmon D, Picard C, et al "Penile ulcerations with foscarnet." Lancet 335 (1990): 547-8
Deray G, Katlama C, Dohin E "Prevention of foscarnet nephrotoxicity." Ann Intern Med 113 (1990): 332
Lacey HB, Ness A, Mandal BK "Vulval ulceration associated with foscarnet." Genitourin Med 68 (1992): 182